Main text {#Sec1}
=========

Xenon was the first noble gas receiving thorough scientific interest starting in the field of decompression sickness of divers. In mice, the first experiments by Lawrence et al. described slightest signs of dizziness and movement disorders beginning from 60% of xenon \[[@CR1]\]. The use of xenon as a general anaesthetic was first described in 1951 \[[@CR2]\]. The low blood-gas and brain-blood coefficients, rapid induction and recovery from anaesthesia \[[@CR3]\], almost no respiratory, hepatic or renal toxicity, stable haemodynamics, and effective organ protective properties in multiple animal models have made xenon a near "ideal" anaesthetic. Xenon has been shown to be safely applicable in patients, even in children \[[@CR4]--[@CR15]\]. Early clinical trials have shown the haemodynamic stability of xenon anaesthesia. The peripheral vascular resistance is increased. This increase leads to a higher mean arterial pressure, a lower heart frequency and a lower cardiac output compared to other inhalational anaesthetics or propofol \[[@CR3], [@CR6], [@CR13], [@CR14], [@CR16]--[@CR20]\]. A clinically relevant unpleasant side effect of xenon, despite its inhibition of 5-HT~3~-receptors, is the increase in postoperative nausea and vomiting (PONV) compared to propofol anaesthesia \[[@CR5], [@CR21]--[@CR23]\].

Several narrative and systematic reviews have summarized the results from laboratory findings regarding the mechanistic understanding of the biological action of xenon \[[@CR24]--[@CR30]\].

An overview of the known molecular mechanisms of xenon is shown in Table [1](#Tab1){ref-type="table"}. Table 1Molecular mechanism of xenonXenonAuthorEffects revealed in humanEffects revealed in in vivoEffects revealed in in vitroOrganprotectionYakamura and Harris \[[@CR31]\]Non-competitive blockade of NMDA receptors and nACH (*N*-acetyl-choline receptors nACH)Li et al. \[[@CR32]\]mitoKATPchannelHeartGruss et al. \[[@CR33]\]Activation of two-pore-domain K^+^channel (TREK-1)BrainMa et al. \[[@CR34]\]Hypoxia inducible factor 1α↑ EPO ↑, VEGF↑mTOR expression↑RenalZhao et al. \[[@CR35]\]IGF-1↑, HIF 1α↑, NF-κB↓RenalDinse et al. \[[@CR36]\]Blocks AMPA. receptor & kainate receptorsBrainBantel et al. \[[@CR37]\]K~ATP~ -- OpenerBrainWeber et al. \[[@CR38]\], Weber et al. \[[@CR39]\], Pravdic et al. \[[@CR40]\]Protein kinase C (PKC)-ε, EKR1/2P38MAPK, HSP 27, JNKHeartLuo et al. \[[@CR41]\]PI3K SignalingBrainBanks et al. \[[@CR42]\],Competitive NMDA receptor inhibitionBrainHarris et al. \[[@CR43]\],Competitive NMDA receptor inhibitionActivation of TREK-1 channelsBrainFranks et al. \[[@CR44]\]Inhibition of NMDA receptorBrain↑ upregulation; ↓ downregulation; ≈ no changes, blockade; *AMPA* a-amino-3-hydroxy-5-methyl-4-isoxazolole propionate, kainate; *Bcl-2* B cell lymphoma 2; *GABAA receptor* gamma-aminobutyric acid A receptor; *LPS* lipopolysaccharide; *ERK1/2* extracellular signal-regulated kinases 1/2; MEK1/2 = *MAPKK* mitogen-activated protein kinase; *mTOR* mammalian target of rapamycin; *Nrf2* nuclear factor (erythroid-derived 2)-like 3; *TLR* Toll-like receptor; *NF-κB* nuclear factor "kappa-light-chain-enhancer" of activated B cells

Cardioprotection by xenon {#Sec2}
-------------------------

In different experimental myocardial infarction models, xenon led to a relevant infarct size reduction as already known for isoflurane and sevoflurane \[[@CR38], [@CR39], [@CR45]--[@CR48]\]. Xenon given in pre-, peri- and postconditioning models has been shown to act on different effectors of the Survivor Activation Factor Enhancement (SAFE) pathway as well as the Reperfusion Injury Salvage Kinase (RISK) pathway \[[@CR29], [@CR38], [@CR39], [@CR46], [@CR49], [@CR50]\]. Animal studies have shown a better recovery of the stunned myocardium after ischaemia-reperfusion injury under xenon anaesthesia \[[@CR49], [@CR51]\]. A detailed description of the cardioprotective mechanism by xenon was gathered by Smit et al. \[[@CR30]\]. Transferring results from one species to another is difficult, as inflammatory reactions in rodents differ from inflammatory reactions in pigs. However, the transfer from an acute myocardial pig infarction model \[[@CR45], [@CR46]\] to a chronic infarction model (4-week follow-up) in rats \[[@CR52]\] underlined the cardioprotective properties of xenon. Following the demonstrated clinical cardiac stability and promising experimental infarct size reduction of xenon, an international, randomized clinical trial on the effect of xenon anaesthesia compared to sevoflurane and total intravenous anaesthesia for coronary artery bypass surgery was performed by Hofland et al. \[[@CR53]\]. A total of 492 patients were randomized to receive either propofol, sevoflurane or xenon. As a primary outcome, the troponin I concentration was measured at 24 h postoperatively. For the first time, the cardioprotective properties of xenon were shown in patients. The troponin I reduction between xenon and propofol was significant. Sevoflurane showed the same extent of troponin I reduction. However, the impact of this observed reduced troponin I release (10 μg/l difference) on the postoperative outcome (30 days mortality, 1-year mortality) is difficult to determine. The translation of myocardial protection from the animal laboratory to cardiovascular surgery is quite difficult \[[@CR54]\]. The ischaemia-reperfusion injury by cardioplegic solution and cardiac surgery itself commonly is quite small. The anaesthetic regimen (especially propofol) \[[@CR55]\], surgical approach and cardioplegia/preservation may diminish the cardioprotective effect by xenon, as several substances, such as antihypertensive medication, similarly show cardioprotective properties \[[@CR56], [@CR57]\].

Neuroprotection by xenon {#Sec3}
------------------------

Cardiac arrest due to ventricular fibrillation is the most life-threatening complication after myocardial infarction (1 out of 20 myocardial infarctions) \[[@CR58]\]. Complete neurologic recovery is still the utmost therapy goal. Despite best efforts, up to 60% of the patients are neurologically or mentally disabled \[[@CR59]\]. In this context, a substance with manifold organ protective properties would be of high interest.

The *N*-methyl-[d]{.smallcaps}-aspartate (NDMA) receptor is partly responsible for hypoxia-ischaemia-induced brain injury \[[@CR60]\]. In vitro cardiac and neuroprotection of xenon is mediated by the inhibition of the excitatory NMDA receptor channels \[[@CR24], [@CR44], [@CR61], [@CR62]\]. In vitro models using glycine as a co-agonist of the NMDA receptor \[[@CR42]\] as well as models of traumatic brain injury \[[@CR43]\] could prove this mechanism of neuroprotection by xenon. This effect suggested that xenon might display a high neuroprotective potential. Another mechanism of possible neuroprotection by xenon has been shown by the modulation of two-pore potassium channels (TREK-1) \[[@CR63]\]. Mild hypothermia has been clinically proven to be neuroprotective after cardiac arrest and perinatal asphyxia \[[@CR64]\]. The first experiments in mice by Limatola et al. showed smaller cerebral infarct sizes when xenon (70%) was applied at 24 h before an ischaemic stroke. The upregulation of hypoxia inducible factor 1-α (HIF1-α) and anti-apoptotic B cell lymphoma (Bcl-2) was identified as possible mechanisms in xenon-treated animals \[[@CR65]\]. Fries and colleagues were the first to show that xenon application at 60 min after CPR in pigs showed a better neurological outcome in the first three treatment days \[[@CR66]\]. Reduced perivascular inflammation was observed in histopathologic examinations. Additional hypothermia reinforced the neuroprotective properties in this animal model \[[@CR67]\]. This inflammation process after neurotrauma has a main impact on the extent of tissue damage and on the neuronal reparation process \[[@CR68]\]. Neuroprotection was clinically observed as a significant improvement in the functional outcome of the animals and a further reduction in perivascular inflammation. The application of 30 or 45 Vol% xenon after 70 min of focal cerebral ischaemia \[[@CR69]\] was only proven in combination with cerebral hypothermia to have a relevant impact on minimizing the neurologic outcome after 28 days in rats. These promising data were supported by Chakkarapani et al. investigating the effect of xenon and hypothermia in asphyxiated newborn pigs \[[@CR70]\]. Xenon-treated animals showed significant improvements in histological and neurological improvement, although the animal survival only lasted up to 3 days. A feasibility study in preterm infants (*n* = 14) using xenon (50%) as an additional neuroprotectant compared to 72 h of hypothermia \[[@CR12]\] showed no adverse effects. However, neuroprotective effects could not be demonstrated in this small cohort. Azzopardi et al. studied the effect of xenon in combination with hypothermia vs hypothermia alone in 92 infants with birth asphyxia \[[@CR71]\]. Due to technical difficulties, the study was terminated prematurely. The sample size did not show significant neuroprotective properties in the different treatment groups. Another pilot study examined patients with out-of-hospital cardiac arrest (*n* = 36). The application of xenon in combination with hypothermia lasted for 24 h \[[@CR72]\]. In addition to the clinically stable application in these high-risk patients, no relevant neurologic improvement could be shown. In a double-blind RCT, 110 comatose patients after cardiac arrest were randomized either to hypothermia alone or to hypothermia and xenon (68 Vol% inhaled) \[[@CR73]\]. The diffusion tensor imaging revealed significantly less white matter damage measured by fractional anisotrophy in xenon-treated patients. This morphologic pattern did not lead to any neurologic clinical difference between the surviving patients in the two groups. This finding might be due to the small number of patients. Additionally, the time point of cooling varied relative to those showing neuroprotection by xenon in animal studies. The timing of xenon application in regard to neurologic injury (before, during or after the injury takes place) seems to have a relevant impact on the potential of the neuroprotective properties of xenon.

As mentioned above, the increase in the peripheral vascular resistance of xenon leads to an increase in cerebral blood flow \[[@CR74], [@CR75]\]. The only clinical trial (*n* = 13) using xenon (33 Vol%) in patients with head injury showed no cerebral decrease in perfusion due to increased blood flow by xenon anaesthesia, albeit increased intracranial pressure \[[@CR76]\].

Another interesting aspect of neuroprotection is the potential reduction in postoperative cognitive deficit (POCD) by anaesthetic agents. The effect of anaesthetic agents and techniques on POCD is an ongoing matter of discussion. Several POCD risk factors that may be influenced interact with GABAerig signalling, such as other inhalational anaesthetics \[[@CR77]\]. As xenon has no activity on GABA receptors \[[@CR29]\], this gas might be a potential effector for minimizing POCD due to anaesthetic regimen. Two pilot studies in elective non-cardiac surgery (*n* = 38, *n* = 40) in patients (65--75 years) failed to show a decline in POCD \[[@CR3], [@CR78]\], probably due to the "too-healthy" collective. Bronco et al. demonstrated that xenon-treated patients (*n* = 60) had better cognitive recovery at 30 and 60 min after non-cardiac surgery compared to sevoflurane anaesthesia \[[@CR19]\]. As patients after xenon anaesthesia showed faster emergence of anaesthesia than patients treated with sevoflurane, these results are not surprising. Interesting data regarding long-term outcomes are missing in this paper. An international multicentre phase II study (*n* = 256, xenon 60%) by Coburn et al. \[[@CR8]\] performed a deeper examination of postoperative delirium (POD) in a high-risk population of elderly hip-fracture surgery patients up to 4 days after surgery. BIS monitoring was performed in all patients to exclude anaesthetic depth as a confounding factor. Xenon led to an overall POD reduction of 33% compared sevoflurane anaesthesia in this patient cohort. Due to the strict inclusion criteria, the incidence of POD was much smaller than expected from the literature in both groups. Therefore, the trial was underpowered to find statistical significance. The extent of injury due to anaesthesia leading to postoperative cognitive deficit has to be further elucidated, as the results are confounded by many other variables, such as intraoperative medication and haemodynamics, co-medication, postoperative care and duration of the procedure, e.g., the translation of positive results on neuroprotection by xenon from bench to bedside has not yet reached a clinical breakthrough. However, a recently published experimental study in mice by Campos-Pires et al. \[[@CR79]\] provides a promise that neuroprotection by noble gases might still be worth for further research in this field. In an outstanding long-term experiment (20-month follow-up after traumatic brain injury), the cognitive function and survival rates were significantly improved by xenon in mice. Xenon treatment (70--75 Vol%) was initiated at 15 min after injury and lasted for 3 h. This experiment could show all the previously described beneficial properties of neuroprotection by xenon in one experiment: xenon treatment in this model reduced the loss of white matter and reactive astrogliosis known as long-term neuropathologic markers for traumatic brain injury. Especially in the CA1 and dentate gyros areas of the hypothalamus, xenon significantly preserved the number of intact neurons equivalent to the animals without traumatic brain injury. This neuropathological improvements in xenon-treated animals after TBI impeded late-onset hippocampus-dependent memory impairment.

Nephroprotection by xenon {#Sec4}
-------------------------

Acute kidney and liver injury after major cardiovascular surgery has an important impact on perioperative mortality. Hypoperfusion, inflammation and microembolism result in up to 30% of acute kidney failure (AKI) \[[@CR80]\]. Experimental set-ups showed the relevant neuroprotective effects of xenon preconditioning in renal ischaemia-reperfusion injury \[[@CR34]\]. As acute kidney injury is a risk factor after major cardiovascular surgery \[[@CR80]\], a therapeutic agent with multiple organ protective properties would be of high interest. Ma et al. showed that 2 h of xenon anaesthesia (70 Vol%) before a renal ischaemia-reperfusion injury led to a 10-fold reduction in creatinine excretion in mice. Creatinine in xenon-treated animals normalized within 20 days. The major finding by Ma was the first proof of the upregulation of HIF-1α and the consecutive increase in erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in xenon-treated animals. This erythropoietin increase is a downstream effector of the mammalian target of rapamycin (mTOR) pathway. Erythropoietin increase has a preconditioning and thereby organ protective effect in experimental ischaemia-reperfusion injury \[[@CR81]\]. In a randomized controlled single centre trial, xenon (60 Vol%) was compared to isoflurane (1.2 Vol%) anaesthesia for nephroprotection in 46 patients who underwent partial nephrectomy with consecutive kidney ischaemia-reperfusion injury \[[@CR82]\]. Xenon was equivalent to isoflurane anaesthesia, although not superior in regard to postoperative renal function in this relatively small cohort. This finding might be due to the relevant small ischaemia-reperfusion injury in this collective.

Apparently, xenon has been used for doping purposes due to its activation of HIF1-α \[[@CR83]\] by Russian teams for endurance sports, such as biathlon, cross-country-skiing, e.g., during the Olympic winter games in Sotchi 2014 \[[@CR84]\]. Since September 2014, xenon and argon have been added to the Prohibited List by the World Anti-Doping Agency (WADA) due to their activation of hypoxia tolerating factors, such as EPO and VEGF \[[@CR85]\]. The minimal dose of xenon necessary to induce relevant HIf-1α is not yet known. The inhalation of subanaesthetic doses of xenon leads to a significant increase in HIf-1α followed by an up to 160% increase in EPO and VEGF \[[@CR85]\]. Erythropoetin stimulation by xenon could be an interesting long-term benefit, for example, in patients with cerebral vasospasms. The injection of 30,000 IU of EPO for 3 days leads to a relevant reduction in the severity of cerebral vasospasm \[[@CR86], [@CR87]\]. By analysing blood, exhalation and urine samples of patients under xenon exposure, EPO elevation has been proven for 24 h \[[@CR88]--[@CR91]\]. In an RCT trial, 30 cardiac surgery patients received either xenon or sevoflurane. Stoppe et al. measured significantly elevated EPO concentrations in xenon-treated patients on the first postoperative day \[[@CR91]\]. Even subanaesthetic doses of 30 Vol% xenon for 45 min lead to an increased EPO level in healthy volunteers \[[@CR92]\]. The peak level was reached at 8 h after xenon exposure and remained elevated for up to 96 h. These are major differences in hypoxemia-induced erythropoietin stimulation, which only lasts up to 2 h \[[@CR93]\]. This point might be of interest for further studies on the role of xenon as a possible neuroprotectant.

The use of xenon is licenced for adult anaesthesia in Europe \[[@CR94]\]. Different manufacturers have developed anaesthesia circuits for xenon application, e.g., Air Liquide, EKU, Dräger. In addition to develop xenon-feasible anaesthesia circuits, the different measuring technologies and the calibration of flow sensors for xenon gas concentrations are challenging \[[@CR95]\]. Commonly used thermal conductivity flow sensors in anaesthesia circuits have a measurement error of up to 10% of the actual xenon concentration due to the low heat conductance of xenon. Flow sensors based on ultrasound or laser refractometry show much better accuracy at lower costs. Incorrect measurement of xenon might lead to an unselected increase in xenon dosage, while xenon costs up to 20€/l \[[@CR96]\]. In contrast, argon costs approximately 9c/l. Due to the recent changes in the Act on Medical Devices in European legislation, licenced anaesthesia circuits would have to renew their licence. In fact, there is no xenon-feasible anaesthesia circuit available at present, since the devices from Draeger, Air Liquide and EKU have been taken off the market. In small-animal experiments, fixed air-gas mixtures are used. The application of these manufactured air-gas mixtures would require up to four times more xenon than in closed or semi-closed anaesthesia circuits. Due to the high price of xenon as a consequence of the technical challenges of xenon extraction and constructing xenon anaesthesia circuits, the focus on organ protective noble gases has shifted towards argon. The main advantages of argon are its low cost, ease of transport and lack of anaesthetic properties under atmospheric pressure \[[@CR97]\]. These advantages are of high value regarding any application in patients with stroke or any other cause of neuronal damage. The main focus in experimental settings of argon has been thus far on its neuroprotective properties.

Neuroprotection by argon {#Sec5}
------------------------

Although the mechanisms of neuronal injury vary widely, the main goal of any neuroprotective agent will be to attenuate injury progression and diminish secondary injury due to hypoxia or ischaemia-reperfusion injury. Ideally, these mechanisms will lead to reduced neuronal and glial inflammation. These factors influence or even interrupt neuronal apoptosis, mitochondrial dysfunction and excitoxicity. Systematic reviews by Hoellig \[[@CR98]\], Ulbrich \[[@CR99]\] and Nespoli \[[@CR100]\] have provided detailed information about the molecular pathways of neuroprotection mediated by argon (Table [2](#Tab2){ref-type="table"}). Table 2Molecular mechanism of argonArgonAuthorEffects revealed in humanEffects revealed in in vivoEffects revealed in in vitroOrganprotectionLoetscher et al. \[[@CR101]\], Fahlenkamp et al. \[[@CR102]\], Ulbrich et al. \[[@CR103]\]Activation of MEK-ERK 1/2pathwayBrainAbraini et al. \[[@CR104]\]Binding to GABA~A~-receptorBrainFahlenkamp et al. \[[@CR105]\]↑ IL-1beta, ↑IL-6, ↑iNOS, ↑TGF-beta,BrainZhuang et al. \[[@CR106]\]↑ Bcl-2BrainUlbrich et al. \[[@CR110]\]Inhibition TLR 2/4BrainUlbrich et al. \[[@CR103]\]↑ERK1/2,↑Heme-oxygenase-1BrainZhao et al. \[[@CR108]\]PI3K Signaling, ↑Nrf2Brain↑ upregulation; ↓ downregulation; ≈ no changes, blockade; *AMPA* a-amino-3-hydroxy-5-methyl-4-isoxazolole propionate, kainate; *Bcl-2* B cell lymphoma 2; *GABAA receptor* gamma-aminobutyric acid A receptor; *LPS* lipopolysaccharide; *ERK1/2* extracellular signal-regulated kinases 1/2; MEK1/2 = *MAPKK* mitogen-activated protein kinase; *mTOR* mammalian target of rapamycin; *Nrf2* nuclear factor (erythroid-derived 2)-like 3; *TLR* Toll-like receptor; *NF-κB* nuclear factor "kappa-light-chain-enhancer" of activated B cells

Different in vitro models of argon application in organotypic hippocampal slices proved the neuroprotective properties of argon at 1 h and 2 h after neurologic injury \[[@CR101]\]. The best effect in vivo was shown for a concentration of 50 Vol% inhaled argon \[[@CR101]\]. Recently, Koziakova et al. compared the neuroprotective effects of xenon and argon in the same model of organotypic hippocampal brain slices \[[@CR109]\]. Both substances impaired the neurologic injury to the same extent. Additionally, the neuroprotective effect of xenon was abolished by glycine. This finding underlines the neuroprotective properties of xenon mediated via the inhibition of the NMDA receptor glycine site. Neuroprotection by argon was not impaired by glycine. The detailed pathway of neuroprotection by argon still has to be elucidated.

Models of global cerebral ischaemia with the inhalation of 70 Vol% argon for 1 h after cardiopulmonary resuscitation (CPR) in rats underline the neuroprotective properties of argon in vivo. Histopathological damage in the cortex and hippocampal region was reduced, resulting in an improved functional neurological outcome up to 3 days after injury. This improvement was even shown by applying argon 1 delayed hour after CPR \[[@CR110], [@CR111]\]. Following these promising results, argon was added to mild hypothermia in the same model. This addition is because hypothermia is currently the only proven neuroprotective method in humans \[[@CR64]\]. Argon added to hypothermia compared to animals treated with hypothermia alone, which showed worse neurologic outcomes and the deterioration of histopathologic results. These results need to be further explored. Other models tested for the neuroprotective effects of argon are experimental stroke models or models of experimental subarachnoid haemorrhage. Applying argon (50 Vol%) either during ischaemia or after reperfusion (24 Vol%) for 3 h in a transient middle cerebral artery occlusion model reduced the infarct size \[[@CR112], [@CR113]\]. These experiments did not lead to an improvement in neurologic outcome. Recently, Ma et al. \[[@CR114]\] proved that argon (70 Vol%) applied for 24 h in a MCAO model relevantly improved the neurologic outcome and reduced the final infarct volumes.

Inflammation plays a major role after stroke by aggravating neuronal damage in the penumbra \[[@CR86], [@CR115]\]. Fahlenkamp et al. showed that argon reduces LPS-induced inflammation in microglia cell cultures \[[@CR102]\]. Fore a deeper mechanistic understanding of neuroprotection by argon models of apoptosis in human neuroblastoma cells and ischaemia reperfusion were established by Ulbrich et al. \[[@CR99], [@CR107], [@CR116]\]. Ulbrich et al. identified the inhibition of Toll-like receptors (TLR2/TLR4) and the activation of the NF-κB pathway by argon as relevant regarding the reduction in microglial inflammation. Initial microglial activation in ischaemic stroke is highly attributed to blood-brain barrier disruption \[[@CR115]\]. Due to these results, the focus of neuroprotection by argon is on the ischaemic boundary zone. An experimental MCAO model in rats by Liu et al. \[[@CR117]\] did not have any impact on the infarct volume. However, Liu showed that argon has an impact on microglial inflammation in vivo \[[@CR117]\].. Argon (50 Vol%) application at 3 h after the onset of stroke and at 1 h after reperfusion led to a decrease in microglial inflammation in the ischaemic border zone. The anti-inflammatory M2 phenotype of microglia was upregulated in this model. This positive influence on neuronal recovery in the ischaemic boundary zone at 7 days after reperfusion resulted in a significant reduction in neurologic deficit. The microglia activation by ischaemia-reperfusion injury leads to an increase in oxidative stress, inflammation and apoptosis \[[@CR118]\]. Ma et al. applied argon (70%) for 24 h in a permanent MCAO model in rats onset 2 h after ischaemia \[[@CR114]\]. In this model, infarct volume and 7-day mortality were not significantly reduced in argon-treated animals. However, surviving animals showed a significant improvement in neurologic outcome. Reperfusion activates microglia. The activation of microglia is associated with oxidative stress, inflammation and apoptosis. These three factors have been shown to have a deleterious impact on ischaemic stroke \[[@CR115], [@CR119]\]. Recent evidence shows a biphasic role for microglia. Therefore, a deeper investigation of the long-term effect of argon on microglial activation should be performed. Perhaps this finding could explain the different infarct-size reduction effects of argon depending on the time point of argon application. If there is a long-term reduction in microglial activation by argon, this effect might influence the shift from a detrimental to a beneficial microglial phenotype \[[@CR115]\].

In kidney transplantation, ischaemia-reperfusion injury is predictable. Three different experimental models investigated the renoprotective properties of argon. In rats, argon-saturated storage solution significantly improved renal function, even up to 14 days posttransplantation \[[@CR120]\]. In a pig model of heterotropic renal autotransplantation, saturation of the extracellular preservation solution with argon showed acute and long-term (21 days) positive impacts on ischaemia-reperfusion injury \[[@CR121]\]. Meanwhile, postconditioning with argon for impairment of renal ischaemia-reperfusion injury (IRI) does not improve kidney graft function in a similar porcine autotransplantation model \[[@CR122]\]. Argon (70 Vol%) applied before aortic cross clamping attenuated ischaemia-reperfusion injury to multiple organs in a rabbit model \[[@CR123]\]. It needs further studies to clarify the role of argon on the attenuation of the ischaemia-reperfusion injury leading to a long-term improvement in kidney function.

Argon in human patients {#Sec6}
-----------------------

Clinically, fixed argon-oxygen concentrations are used as an indicator for cerebrovascular CO~2~-reactivity of cerebral blood flow \[[@CR124], [@CR125]\]. The growing interest in possible clinical settings led to a deeper look at this established argon inhalation in human physiology as a proof of principle. In 30 patients prior to cardiac surgery, argon was applied for 15 min only. Inhalation of argon did not increase cerebral perfusion, global oxygen consumption or glucose metabolism in this cohort. To apply argon for human use, a feasible application method needs to be developed. In a short correspondence by Cucino et al. \[[@CR126]\], a modified anaesthesia circuit (Bellavista 1000, IMT Medical, Buchs) was used to deliver 70% argon and 30% oxygen in pigs regarding the promising argon concentration for neuroprotection. This is a promising opportunity for standardizing argon while ventilating patients under critical conditions. Fixed argon-oxygen mixtures used in animal experiments will be less comfortable for use in critically ill patients. As we have no clinical experience with argon application in humans, new insights into the pulmonary vascular tone in rats and humans have been reported by Suleiman et al. \[[@CR127]\]. These cell culture experiments present the first evidence that unlike xenon, argon will not be irritating to the airways. Additionally, it could be shown that argon decreases the pulmonary vessel tone due to GABA receptor activation. This effect might be of high value if argon-treated patients show relevant comorbidities, such as right ventricular failure or pulmonary hypertension.

Conclusions {#Sec7}
-----------

One of the main questions remains. Why do we still lack to transfer these promising results of experimental neuroprotection by noble gases to clinical settings? There is now a wide mechanistical understanding of organprotection by xenon. The clinical robustness of xenon anaesthesia has been proven. These positive findings highly enforce further interest in organprotection by noble gases. The high price of xenon and the lack of available xenon-capable ventilators will impede further clinical trials on xenon. Therefore, effort should be put into developing ventilators feasible for xenon or argon anaesthesia. This development will take some time due to manufacturing cycles and legislative requirements. Therefore, it might be tempting to use fixed air-argon concentrations for the first clinical trials, although these methods also have to be accredited. Dingley et al. developed a portable delivery device for xenon application children after perinatal asphyxia \[[@CR128]\]. By this device, xenon application was feasible within 5 h after birth. This device is not yet commercially available.

One main commonality in all experimental organ protective studies is that no propofol is used in the animal setting for the induction of anaesthesia. Most inhalation agents or the intraperitoneal application of thiopental are used for anaesthesia induction in animals. If propofol itself exceeds cardioprotective properties or adversely attenuates protection, then the experiment is not yet conclusive due to the available data. Indeed, propofol is ubiquitous for the induction of human anaesthesia worldwide. Recently, research focused on the impact of propofol on promoting/inhibiting remote-ischaemic preconditioning, anaesthetic organ protection, neuroprotection by reducing/increasing POD, etc. \[[@CR55], [@CR129]--[@CR133]\].

Consensus papers have been published for planning preclinical and human trials in myocardial per- and postconditioning \[[@CR56]\] for stroke therapy (Stroke Therapy Acute Industry Roundtable STAIR recommendations) \[[@CR92]\] and for traumatic brain injury \[[@CR134], 138\]. STAIR recommendations first published in 1999 have not been implemented in many animal models until 2015, as reviewed by Thomas et al. \[[@CR135]\]. Most likely, consensus studies on neuroprotection by noble gases would help to focus on comparable protocols in experimental studies, for example, comparable anaesthesia induction, maintenance and pain therapy. Currently, there is a wide mechanistic understanding of how argon promotes organprotection, mostly centred on insights into neuroprotection and in acute to short-term models (less than 7 day survival). These results are highly promising. Perhaps long-term models, such as those described for traumatic brain injury by Campos-Pires \[[@CR79]\], could enforce the upscaling from short-term experimental settings to human trials.

One main difference between experimental and clinical trials with xenon for neuroprotection after resuscitation or neonatal asphyxia is the time window of xenon application. In animal studies, the time window ranges from 1 to 5 h \[[@CR69]\], over 3 h \[[@CR136]\] up to 4 h \[[@CR137]\] after the timepoint of defined neuronal injury. In the human, Xe-Hypotheca trial (xenon application combined with hypothermia after out of hospital arrest) started 5 h after the incident what comes close to the therapeutic time-windows identified in animal trials \[[@CR52]\]. Xenon treatment lasted up to 72 h and resulted in a significantly reduced release in troponin T. This pilot trial would be worth giving xenon a trial in bigger randomized clinical trials.

In contrast, the Toby-XE trial (xenon application starting within the first 6 h after onset of neonatal hypoxic-ischemic brain injury) could not prove any neuroprotective effects \[[@CR71]\]. Both human trials showed the feasibility of applying xenon in emergency situations in patients with a relevant cell injury. The time delay in xenon application compared to experimental settings seems to have a relevant impact on the potency of neuroprotection.0

In preclinical trials, the organ protective effects have to be investigated in senescent, co-medicated and animals of different sexes. Planning clinical translation should focus on trial efficacy, robustness, clinical relevance, therapeutic window, interactions with other standard therapies (revascularization, hypothermia), physiologic monitoring, outcome measures, sex and age, co-medication differences, etc. Additionally, electronical data recording for any preclinical and clinical trials might elucidate further aspects of neuroprotection by noble gases using big data analysis. At least standardized charts leading to a database for experimental set-ups could be worth considering.
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